APO Research
Talk to an analyst

APO RESEARCH · REPORT

Large Molecule Drugs CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Large Molecule Drugs CDMO Market Outlook and Growth Opportunities 2026

1 May 2026191 pages

Choose your research edition.

Industry ResearchLarge Molecule Drugs CDMO Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Large Molecule Drugs CDMO Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Large Molecule Drugs CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Large Molecule Drugs CDMO Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Large Molecule Drugs CDMO Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Large Molecule Drugs CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Large Molecule Drugs CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Large Molecule Drugs CDMO market include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Large Molecule Drugs CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Large Molecule Drugs CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Large Molecule Drugs CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Large Molecule Drugs CDMO market.

Large Molecule Drugs CDMO Segment by Company

Patheon

Eurofins Scientific

Samsung Biologics

Catalent, Inc.

Rentschler Biopharma SE

AGC Biologics

Recipharm AB

Siegfried Holding AG

FUJIFILM Diosynth Biotechnologies

Scorpius

Ardena

Alcami

Cytiva

Thermo Fisher Scientific

Large Molecule Drugs CDMO Segment by Type

Cell Line Development

Large Molecule Drug Substance Development

Large Molecule Drugs CDMO Segment by Application

Biological Technology

Clinical

Pharmaceutical

Others

Large Molecule Drugs CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Large Molecule Drugs CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Large Molecule Drugs CDMO key companies, revenue, market share, and recent developments.

3. To split the Large Molecule Drugs CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Large Molecule Drugs CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Large Molecule Drugs CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Large Molecule Drugs CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Large Molecule Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Large Molecule Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Large Molecule Drugs CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Large Molecule Drugs CDMO industry.

Chapter 3: Detailed analysis of Large Molecule Drugs CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Large Molecule Drugs CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Large Molecule Drugs CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Large Molecule Drugs CDMO Industry Trends Table 2. Large Molecule Drugs CDMO Industry Drivers Table 3. Large Molecule Drugs CDMO Industry Opportunities and Challenges Table 4. Large Molecule Drugs CDMO Industry Restraints Table 5. Global Large Molecule Drugs CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Large Molecule Drugs CDMO Revenue Share by Company (2021-2026) Table 7. Global Large Molecule Drugs CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Large Molecule Drugs CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Large Molecule Drugs CDMO Company, Product Type & Application Table 10. Global Large Molecule Drugs CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Large Molecule Drugs CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cell Line Development Table 15. Significant Companies of Large Molecule Drug Substance Development Table 16. Global Large Molecule Drugs CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Large Molecule Drugs CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Large Molecule Drugs CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Large Molecule Drugs CDMO Sales Value Share by Type (2021-2026) Table 20. Global Large Molecule Drugs CDMO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Biological Technology Table 22. Significant Companies of Clinical Table 23. Significant Companies of Pharmaceutical Table 24. Significant Companies of Others Table 25. Global Large Molecule Drugs CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Large Molecule Drugs CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Large Molecule Drugs CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Large Molecule Drugs CDMO Sales Value Share by Application (2021-2026) Table 29. Global Large Molecule Drugs CDMO Sales Value Share by Application (2027-2032) Table 30. Global Large Molecule Drugs CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Large Molecule Drugs CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Large Molecule Drugs CDMO Sales Value Share by Region (2021-2026) Table 33. Global Large Molecule Drugs CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Large Molecule Drugs CDMO Sales Value Share by Region (2027-2032) Table 35. Global Large Molecule Drugs CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Large Molecule Drugs CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Large Molecule Drugs CDMO Sales Value Market Share by Country (2021-2026) Table 38. Global Large Molecule Drugs CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Large Molecule Drugs CDMO Sales Value Market Share by Country (2027-2032) Table 40. Patheon Company Information Table 41. Patheon Business Overview Table 42. Patheon Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Patheon Large Molecule Drugs CDMO Product Portfolio Table 44. Patheon Recent Development Table 45. Eurofins Scientific Company Information Table 46. Eurofins Scientific Business Overview Table 47. Eurofins Scientific Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio Table 49. Eurofins Scientific Recent Development Table 50. Samsung Biologics Company Information Table 51. Samsung Biologics Business Overview Table 52. Samsung Biologics Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Samsung Biologics Large Molecule Drugs CDMO Product Portfolio Table 54. Samsung Biologics Recent Development Table 55. Catalent, Inc. Company Information Table 56. Catalent, Inc. Business Overview Table 57. Catalent, Inc. Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio Table 59. Catalent, Inc. Recent Development Table 60. Rentschler Biopharma SE Company Information Table 61. Rentschler Biopharma SE Business Overview Table 62. Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio Table 64. Rentschler Biopharma SE Recent Development Table 65. AGC Biologics Company Information Table 66. AGC Biologics Business Overview Table 67. AGC Biologics Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. AGC Biologics Large Molecule Drugs CDMO Product Portfolio Table 69. AGC Biologics Recent Development Table 70. Recipharm AB Company Information Table 71. Recipharm AB Business Overview Table 72. Recipharm AB Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Recipharm AB Large Molecule Drugs CDMO Product Portfolio Table 74. Recipharm AB Recent Development Table 75. Siegfried Holding AG Company Information Table 76. Siegfried Holding AG Business Overview Table 77. Siegfried Holding AG Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio Table 79. Siegfried Holding AG Recent Development Table 80. FUJIFILM Diosynth Biotechnologies Company Information Table 81. FUJIFILM Diosynth Biotechnologies Business Overview Table 82. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio Table 84. FUJIFILM Diosynth Biotechnologies Recent Development Table 85. Scorpius Company Information Table 86. Scorpius Business Overview Table 87. Scorpius Large Molecule Drugs CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Scorpius Large Molecule Drugs CDMO Product Portfolio Table 89. Scorpius Recent Development Table 90. Ardena Company Information Table 91. Ardena Business Overview Table 92. Ardena Large Molecule Drugs CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Ardena Large Molecule Drugs CDMO Product Portfolio Table 94. Ardena Recent Development Table 95. Alcami Company Information Table 96. Alcami Business Overview Table 97. Alcami Large Molecule Drugs CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Alcami Large Molecule Drugs CDMO Product Portfolio Table 99. Alcami Recent Development Table 100. Cytiva Company Information Table 101. Cytiva Business Overview Table 102. Cytiva Large Molecule Drugs CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Cytiva Large Molecule Drugs CDMO Product Portfolio Table 104. Cytiva Recent Development Table 105. Thermo Fisher Scientific Company Information Table 106. Thermo Fisher Scientific Business Overview Table 107. Thermo Fisher Scientific Large Molecule Drugs CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio Table 109. Thermo Fisher Scientific Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Large Molecule Drugs CDMO Product Image Figure 2. Global Large Molecule Drugs CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Large Molecule Drugs CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Large Molecule Drugs CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cell Line Development Image Figure 8. Large Molecule Drug Substance Development Image Figure 9. Global Large Molecule Drugs CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Large Molecule Drugs CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Large Molecule Drugs CDMO Sales Value Share by Type (2021-2032) Figure 12. Biological Technology Image Figure 13. Clinical Image Figure 14. Pharmaceutical Image Figure 15. Others Image Figure 16. Global Large Molecule Drugs CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Large Molecule Drugs CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Large Molecule Drugs CDMO Sales Value Share by Application (2021-2032) Figure 19. Global Large Molecule Drugs CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Large Molecule Drugs CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Large Molecule Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 22. North America Large Molecule Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Large Molecule Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Large Molecule Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Large Molecule Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Large Molecule Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Large Molecule Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. South America Large Molecule Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Large Molecule Drugs CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Large Molecule Drugs CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Line Development
  • Large Molecule Drug Substance Development
Applications
  • Biological Technology
  • Clinical
  • Pharmaceutical
  • Others
Companies covered
  • Patheon
  • Eurofins Scientific
  • Samsung Biologics
  • Catalent, Inc.
  • Rentschler Biopharma SE
  • AGC Biologics
  • Recipharm AB
  • Siegfried Holding AG
  • FUJIFILM Diosynth Biotechnologies
  • Scorpius
  • Ardena
  • Alcami
  • Cytiva
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Large Molecule Drugs CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Large Molecule Drugs CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Large Molecule Drugs CDMO Market Dynamics
  1. 2.1 Large Molecule Drugs CDMO Industry Trends
  2. 2.2 Large Molecule Drugs CDMO Industry Drivers
  3. 2.3 Large Molecule Drugs CDMO Industry Opportunities and Challenges
  4. 2.4 Large Molecule Drugs CDMO Industry Restraints
3 Large Molecule Drugs CDMO Market by Company
  1. 3.1 Global Large Molecule Drugs CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Large Molecule Drugs CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Large Molecule Drugs CDMO Company Ranking (2024-2026)
  4. 3.4 Global Large Molecule Drugs CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Large Molecule Drugs CDMO Company Product Type and Application
  6. 3.6 Global Large Molecule Drugs CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Large Molecule Drugs CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Large Molecule Drugs CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Large Molecule Drugs CDMO Market by Type
  1. 4.1 Large Molecule Drugs CDMO Type Introduction
  2. 4.1.1 Cell Line Development
  3. 4.1.2 Large Molecule Drug Substance Development
  4. 4.2 Global Large Molecule Drugs CDMO Sales Value by Type
  5. 4.2.1 Global Large Molecule Drugs CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Large Molecule Drugs CDMO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Large Molecule Drugs CDMO Sales Value Share by Type (2021-2032)
5 Large Molecule Drugs CDMO Market by Application
  1. 5.1 Large Molecule Drugs CDMO Application Introduction
  2. 5.1.1 Biological Technology
  3. 5.1.2 Clinical
  4. 5.1.3 Pharmaceutical
  5. 5.1.4 Others
  6. 5.2 Global Large Molecule Drugs CDMO Sales Value by Application
  7. 5.2.1 Global Large Molecule Drugs CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Large Molecule Drugs CDMO Sales Value by Application (2021-2032)
  9. 5.2.3 Global Large Molecule Drugs CDMO Sales Value Share by Application (2021-2032)
6 Large Molecule Drugs CDMO Regional Value Analysis
  1. 6.1 Global Large Molecule Drugs CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Large Molecule Drugs CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Large Molecule Drugs CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Large Molecule Drugs CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Large Molecule Drugs CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Large Molecule Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Large Molecule Drugs CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Large Molecule Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Large Molecule Drugs CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Large Molecule Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Large Molecule Drugs CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Large Molecule Drugs CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Large Molecule Drugs CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Large Molecule Drugs CDMO Sales Value Share by Country, 2025 VS 2032
7 Large Molecule Drugs CDMO Country-level Value Analysis
  1. 7.1 Global Large Molecule Drugs CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Large Molecule Drugs CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Large Molecule Drugs CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Large Molecule Drugs CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Large Molecule Drugs CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Large Molecule Drugs CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Large Molecule Drugs CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Patheon
  2. 8.1.1 Patheon Company Information
  3. 8.1.2 Patheon Business Overview
  4. 8.1.3 Patheon Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Patheon Large Molecule Drugs CDMO Product Portfolio
  6. 8.1.5 Patheon Recent Developments
  7. 8.2 Eurofins Scientific
  8. 8.2.1 Eurofins Scientific Company Information
  9. 8.2.2 Eurofins Scientific Business Overview
  10. 8.2.3 Eurofins Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio
  12. 8.2.5 Eurofins Scientific Recent Developments
  13. 8.3 Samsung Biologics
  14. 8.3.1 Samsung Biologics Company Information
  15. 8.3.2 Samsung Biologics Business Overview
  16. 8.3.3 Samsung Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Biologics Large Molecule Drugs CDMO Product Portfolio
  18. 8.3.5 Samsung Biologics Recent Developments
  19. 8.4 Catalent, Inc.
  20. 8.4.1 Catalent, Inc. Company Information
  21. 8.4.2 Catalent, Inc. Business Overview
  22. 8.4.3 Catalent, Inc. Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio
  24. 8.4.5 Catalent, Inc. Recent Developments
  25. 8.5 Rentschler Biopharma SE
  26. 8.5.1 Rentschler Biopharma SE Company Information
  27. 8.5.2 Rentschler Biopharma SE Business Overview
  28. 8.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio
  30. 8.5.5 Rentschler Biopharma SE Recent Developments
  31. 8.6 AGC Biologics
  32. 8.6.1 AGC Biologics Company Information
  33. 8.6.2 AGC Biologics Business Overview
  34. 8.6.3 AGC Biologics Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AGC Biologics Large Molecule Drugs CDMO Product Portfolio
  36. 8.6.5 AGC Biologics Recent Developments
  37. 8.7 Recipharm AB
  38. 8.7.1 Recipharm AB Company Information
  39. 8.7.2 Recipharm AB Business Overview
  40. 8.7.3 Recipharm AB Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Recipharm AB Large Molecule Drugs CDMO Product Portfolio
  42. 8.7.5 Recipharm AB Recent Developments
  43. 8.8 Siegfried Holding AG
  44. 8.8.1 Siegfried Holding AG Company Information
  45. 8.8.2 Siegfried Holding AG Business Overview
  46. 8.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio
  48. 8.8.5 Siegfried Holding AG Recent Developments
  49. 8.9 FUJIFILM Diosynth Biotechnologies
  50. 8.9.1 FUJIFILM Diosynth Biotechnologies Company Information
  51. 8.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
  52. 8.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio
  54. 8.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  55. 8.10 Scorpius
  56. 8.10.1 Scorpius Company Information
  57. 8.10.2 Scorpius Business Overview
  58. 8.10.3 Scorpius Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Scorpius Large Molecule Drugs CDMO Product Portfolio
  60. 8.10.5 Scorpius Recent Developments
  61. 8.11 Ardena
  62. 8.11.1 Ardena Company Information
  63. 8.11.2 Ardena Business Overview
  64. 8.11.3 Ardena Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ardena Large Molecule Drugs CDMO Product Portfolio
  66. 8.11.5 Ardena Recent Developments
  67. 8.12 Alcami
  68. 8.12.1 Alcami Company Information
  69. 8.12.2 Alcami Business Overview
  70. 8.12.3 Alcami Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Alcami Large Molecule Drugs CDMO Product Portfolio
  72. 8.12.5 Alcami Recent Developments
  73. 8.13 Cytiva
  74. 8.13.1 Cytiva Company Information
  75. 8.13.2 Cytiva Business Overview
  76. 8.13.3 Cytiva Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cytiva Large Molecule Drugs CDMO Product Portfolio
  78. 8.13.5 Cytiva Recent Developments
  79. 8.14 Thermo Fisher Scientific
  80. 8.14.1 Thermo Fisher Scientific Company Information
  81. 8.14.2 Thermo Fisher Scientific Business Overview
  82. 8.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio
  84. 8.14.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst